Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Bone Biologics (BBLG) EPS (Weighted Average and Diluted) (2016 - 2017)

Bone Biologics (BBLG) has disclosed EPS (Weighted Average and Diluted) for 2 consecutive years, with $0.02 as the latest value for Q2 2017.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 115.51% to $0.02 in Q2 2017 year-over-year; TTM through Jun 2017 was -$2.83, a 2092.46% decrease, with the full-year FY2025 number at -$2.65, up 90.85% from a year prior.
  • EPS (Weighted Average and Diluted) was $0.02 for Q2 2017 at Bone Biologics, up from -$0.13 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.02 in Q2 2017 to a low of -$0.13 in Q2 2016.